PT Darya-Varia Laboratoria Tbk Stocks

IDR 1600Last Updated 28.04.2026

Issuer Rating

4/7
Performance

Favourable

Risk

Considerable

Recommendation

Hold

Market Cap

IDR 107.52M

Buy
Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
IDR 1600
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Excellent dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

PT Darya-Varia Laboratoria Tbk engages in the manufacture and trading of pharmaceutical products and cosmetics in Indonesia. It operates in three segments: Prescription Drugs, Consumer Health Products, and Export and Toll Manufacturing Services. It provides various prescription and consumer health products in antibiotic, antiparasit, antiseptic, anti-fungal, cough and cold, cardiology, central nervous system, gastro-hepatology, somatic, vitamin and food supplement, women healthcare, ear healthcare, and derma medic areas. The company also exports its products to Malaysia, Myanmar, the Philippines, Singapore, Vietnam, and Mongolia. The company was founded in 1976 and is headquartered in Jakarta, Indonesia. PT Darya-Varia Laboratoria Tbk is a subsidiary of Blue Sphere Singapore Pte. Ltd.

Company Valuation

Fairly valued
4/7

Based on key historical and expected multiples, the stock is fairly valued relative to its peers. In particular, the stock is underpriced on P/E, 'cheap' on EV/EBITDA, tr

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks